• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MIR
Click for more information
0.44% $3.38

MIRRABOOKA INVESTMENTS LIMITED - News & Media

Market Cap $652.7M  ! watchlist Created with Sketch. Add to my watchlist

Mirrabooka Investments Limited is an Australia-based investment company. The Company... Mirrabooka Investments Limited is an Australia-based investment company. The Company specializes in investing in small- and mid-sized companies in Australia and New Zealand. The Company's investment objective is to provide medium to long term investment gains through holding core investments in selected small and medium sized companies (companies which fall outside the S&P/ASX 50 Leaders Index) and to provide attractive dividend returns to shareholders from these investments. The Company's has invested across various sectors, which include consumer discretionary, industrials, other financials, information technology, communication services, healthcare, materials, real estate, energy and consumer staples.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Mirrabooka Investments (ASX:MIR) declares special dividend on strong FY23

Mirrabooka Investments (ASX:MIR) has declared a special dividend following strong performance of its portfolio across FY23.

18 Jul 2023 10:48 (AEST)



(20min delay)
Last
$3.38 		Change
-0.015(0.44%) 		Mkt cap ! $652.7M
Open High Low Value Volume
$3.37 $3.39 $3.36 $72.72K 21.56K

Buyers (Bids)

No. Vol. Price($)
1 32 $3.37
 

Sellers (Offers)

Price($) Vol. No.
$3.38 17606 1
View Market Depth
Last trade - 14.33pm 02/10/2024 (20 minute delay) ?
Last
$3.36 		  Change
-0.015 ( 0.59 %)
Open High Low Volume
$3.37 $3.37 $3.36 5254
Last updated 11.29am 02/10/2024 ?
MIR (ASX) Chart

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
SPC to merge with Original Juice Co and Nature One Dairy The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.